C21 Investments Inc.
CWLXF · OTCMCIK 831609fmd_0X19EA3N0YSAKBA0MH05XS48STManufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Feb 01, 2017 to Mar 31, 2026, 11 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 3 | 38 | 33 | 33 | 29 | 28 | 30 | 33 |
| Cost of revenue | – | 3 | 26 | 15 | 14 | 15 | 17 | 18 | 19 |
| Gross profit | – | 0 | 13 | 18 | 19 | 13 | 11 | 13 | 14 |
| Selling, general and administrative | – | 9 | 10 | 9 | 9 | 9 | 10 | 11 | 11 |
| Compensation and benefits | – | – | – | 3 | 3 | 3 | 3 | 4 | 4 |
| Operating income | (1) | (12) | (1) | 9 | 10 | 4 | 1 | 1 | 2 |
| Interest expense | – | 0 | 4 | 4 | 1 | 0 | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | – | 0 | 0 |
| Income before taxes | (1) | (24) | (29) | (2) | 17 | 4 | 0 | 0 | 1 |
| Income tax expense | 0 | 0 | 4 | 3 | 5 | 3 | 3 | 4 | 5 |
| Net income from continuing operations | (1) | (24) | (33) | (5) | 12 | 1 | (3) | 0 | 1 |
| Net income | (1) | (24) | (33) | (8) | 10 | 0 | (3) | (4) | (3) |